ClinicalTrials.gg
Enrolling by invitationNCT06646354HODO-2224Updated May 22, 2025

To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

A Phase 3 interventional study of Ezetimibe/Rosuvastatin/Candesartan/Amlodipine and Candesartan/Amlodipine in Hypertension and Primary Hypercholesterolaemia, sponsored by Hyundai Pharm. Enrolling by invitation at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by Hyundai Pharm · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing ezetimibe in Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. Ezetimibe · Hypertension.

Planned enrollment
6th of 13
125 · median 65
Started
2025
the only one that year
Phase 3
6 of 13
1 open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
Hyundai Pharm

Among the 13 studies testing ezetimibe in Hypertension, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 3, and was the 12th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 13 studies testing ezetimibe in Hypertension is open now, in 1 country.

By country, each count listing its studies:

Where they have run

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing ezetimibe in Hypertension, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia

Read the detailed description

This trial is a phase 3 study to evaluate the efficacy and safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia.

This is multi-center, double-blind, Active-controlled, parallel-group, phase 3 study.

03

Conditions studied

  • Hypertension
  • Primary Hypercholesterolaemia

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 19
  • Patients with Essential Hypertension and Primary Hypercholesterolemia

Exclusion criteria

Exclusion Criteria:

  • Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP
  • Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    HODO-2224-1+HODO-2224-2+HODO-2224-4

    Oral tablet, QD

    Drug: Ezetimibe/Rosuvastatin/Candesartan/Amlodipine

  • Active comparator
    HODO-2224-1+HODO-2224-4+HODO-2224-5

    Oral tablet, QD

    Drug: Candesartan/Amlodipine

  • Active comparator
    HODO-2224-2+HODO-2224-3+HODO-2224-6

    Oral tablet, QD

    Drug: Candesartan/Rosuvastatin/Ezetimibe

Interventions

06

What researchers measure

Primary outcomes

  1. Low density lipoprotein cholesterol (LDL-C)

    LDL-C change at Week 8 compared HODO-2224-1 + HODO-2224-4 + HODO-2224-5 with HODO-2224

    Time frame: baseline and week 8

  2. Mean sitting systolic blood pressure (MSSBP)

    MSSBP change at week 8 compared HODO-2224-2 + HODO-2224-3 + HODO-2224-6 with HODO-2224

    Time frame: baseline and week 8

Secondary outcomes

  1. change of other Lipid profile

    change of other Lipid profile

    Time frame: 0, 4, 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in May 2025, 0 months.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 0 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 17, 2024
StartActual
Apr 22, 2025
Primary completionActual
May 19, 2025
CompletionEst.
Dec 31, 2028
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06646354
Lead sponsor
Hyundai Pharm
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Apr 22, 2025
Primary completion
May 19, 2025
Completion
Dec 31, 2028 (estimated)
Last update
May 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Rosuvastatin · Candesartan · Amlodipine

Start the discussion